Tyler Borrman

About Tyler Borrman

Tyler Borrman, With an exceptional h-index of 13 and a recent h-index of 13 (since 2020), a distinguished researcher at University of Massachusetts Medical School,

His recent articles reflect a diverse array of research interests and contributions to the field:

EPCO-19. TUMOR-WIDE NEOANTIGEN-SPECIFIC T-CELLS INFILTRATING MUTANT IDH1 LOW-GRADE GLIOMAS AND PERSISTING IN PERIPHERAL BLOOD ALLOW FOR PERSONALIZED TCR-BASED IMMUNOTHERAPIES

370 Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies

Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies

TCR specificity prediction of circulating T cells and TILs in personalized adoptive neoTCR T cell therapy

Monitoring of neoantigens and adoptively transferred personalized neoTCR T cell populations in the tumor and PBMCs of patients with solid tumors

711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L) 1 inhibition

820 Machine learning significantly improves neoantigen-HLA predictions utilizing> 26,000 data points from the PACTImmuneTM Database

Genome-wide mapping of human DNA replication by optical replication mapping supports a stochastic model of eukaryotic replication

Tyler Borrman Information

University

Position

PhD Candidate

Citations(all)

2000

Citations(since 2020)

1861

Cited By

535

hIndex(all)

13

hIndex(since 2020)

13

i10Index(all)

14

i10Index(since 2020)

14

Email

University Profile Page

Google Scholar

Top articles of Tyler Borrman

EPCO-19. TUMOR-WIDE NEOANTIGEN-SPECIFIC T-CELLS INFILTRATING MUTANT IDH1 LOW-GRADE GLIOMAS AND PERSISTING IN PERIPHERAL BLOOD ALLOW FOR PERSONALIZED TCR-BASED IMMUNOTHERAPIES

Neuro-Oncology

2023/11/1

370 Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies

2023/11/1

Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies

Cancer Research

2023/4/4

TCR specificity prediction of circulating T cells and TILs in personalized adoptive neoTCR T cell therapy

Cancer Research

2023/4/4

Tyler Borrman
Tyler Borrman

H-Index: 10

Zheng Pan
Zheng Pan

H-Index: 1

Monitoring of neoantigens and adoptively transferred personalized neoTCR T cell populations in the tumor and PBMCs of patients with solid tumors

Cancer Research

2023/4/4

711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L) 1 inhibition

J Immunother

2022

820 Machine learning significantly improves neoantigen-HLA predictions utilizing> 26,000 data points from the PACTImmuneTM Database

Journal for ImmunoTherapy of Cancer

2021/11/1

Genome-wide mapping of human DNA replication by optical replication mapping supports a stochastic model of eukaryotic replication

Molecular cell

2021/7/15

Liquid chromatin Hi-C characterizes compartment-dependent chromatin interaction dynamics

Nature genetics

2021/3

Performance of ZDOCK and IRAD in CAPRI rounds 39‐45

Proteins: Structure, Function, and Bioinformatics

2020/8

High-throughput modeling and scoring of TCR-pMHC complexes to predict cross-reactive peptides

Bioinformatics

2020/12/1

Tyler Borrman
Tyler Borrman

H-Index: 10

A chromosomal connectome for psychiatric and metabolic risk variants in adult dopaminergic neurons

Genome medicine

2020/12

Measuring Stability of 3D Chromatin Conformations and Identifying Neuron Specific Chromatin Loops Associated with Schizophrenia Risk

2020/11/12

See List of Professors in Tyler Borrman University(University of Massachusetts Medical School)